SCT 400

Drug Profile

SCT 400

Alternative Names: Recombinant chimeric anti-CD20 monoclonal antibody - Sinocelltech; SCT-400

Latest Information Update: 18 May 2016

Price : $50

At a glance

  • Originator Sinocelltech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-Hodgkin's lymphoma

Most Recent Events

  • 18 May 2016 Sinocelltech plans a phase III trial for Diffuse large B cell lymphoma (First-line therapy, Combination therapy) China (NCT02772822)
  • 27 May 2015 Phase-II clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in China (IV) (NCT02456207)
  • 01 Jul 2013 Sinocelltech completes a phase I trial in B-cell lymphoma in China (NCT02206308)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top